4//SEC Filing
Jimenez Freddy A. 4
Accession 0001415889-24-003891
CIK 0000744218other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:05 PM ET
Size
11.5 KB
Accession
0001415889-24-003891
Insider Transaction Report
Form 4
Jimenez Freddy A.
SVP & GENERAL COUNSEL
Transactions
- Exercise/Conversion
Common Stock
2024-02-13$9.02/sh+4,166$37,563→ 5,924 total - Exercise/Conversion
Common Stock
2024-02-13$2.78/sh+20,000$55,600→ 25,924 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-02-13−4,166→ 0 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (4,166 underlying) - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-02-13−20,000→ 0 totalExercise: $2.78Exp: 2029-06-19→ Common Stock (20,000 underlying)
Footnotes (4)
- [F1]On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
- [F2]Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
- [F3]As of June 13, 2022, the option is fully vested.
- [F4]As of June 19, 2023, the option is fully vested.
Documents
Issuer
Celldex Therapeutics, Inc.
CIK 0000744218
Entity typeother
Related Parties
1- filerCIK 0001838114
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 4:05 PM ET
- Size
- 11.5 KB